 PARIS and CAMBRIDGE, Mass., June 30, 2021 GLOBE NEWSWIRE -- Biophytis SA Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS, Biophytis or the company,a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19 today announces topline results for SARA-INT phase 2 study will be released in August 2021. The full results with complete details will be presented during the digital ICSFR scientific medical conference, next September 29-October 2 2021. 